In a large PPMS population that included older patients and people with more advanced disease, ocrelizumab led to a 30% risk ...

Already approved for progressive multiple sclerosis, ocrelizumab in a second phase 3 study demonstrates meaningful clinical ...

Vidofludimus calcium currently is being evaluated in relapsing MS in two phase III trials, ENSURE-1 and ENSURE-2. The phase ...

A combination of metformin, a common diabetes drug, and clemastine, an antihistamine, can help repair myelin—the protective coating around nerves, which gets damaged in multiple sclerosis (MS) causing ...

Multiple sclerosis (MS) could be "on the brink of a new class of treatment" after early trial results suggest two drugs may ...

For decades, multiple sclerosis (MS) research has focused largely on the inflammatory lesions visible on MRI scans. Yet new ...

MS primarily affects young adults and is more common in women. The prevalence continues to rise globally, including in aging ...

The largest study of its kind has found menopause is not associated with an increased risk of disability in women with ...

An analysis found that MS patients on a less frequent anti-CD20 therapy dosing schedule do not have more relapses or show ...

Some older adults with MS on disease-modifying therapies, mainly patients 60 and older, may be able to discontinue DMTs if ...

Compared with low physical activity, the risk of confirmed disability worsening was reduced for people with moderate (HR 0.82 ...

Temperature sensitivity is associated with disease duration, dysautonomia, and quality of life in patients with multiple sclerosis.